{"ticker": {"uuid": "e6fad22a-650f-4d1f-8ebf-42a6331e97cd", "symbol": "FAB", "name": "Fusion Antibodies plc", "exchange": "LSE", "country": "GB", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to EBITDA forward of Fusion Antibodies Plc \u2013 LSE:FAB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxONVUxN0g4NlIwSV9HX0todTZBOWQ4cUY3VGh6LVlfUVh6b1Rxb0dfUG55R0pmc3JrSEVtZHdUVmI5aUxfaXBtcXozUjZlTVVDRjhIRFNPTDVBbHhPTzdtY2p1S0ZCR21qWVFYbmlVSWtrVlkxSTVYLWliSXVSaGpuWUp4Nng3STNVY1p1ZzVHOUp3SUxmQWtGdm1XLVNLdncxRmhibW5FcU8?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T07:53:26+00:00", "published_display": "09 Jul 2026 07:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Fusion Antibodies - Holding(s) in Company", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOSEF5VUY0ZVZBbDExOThjLW1fV2tGZzlMUXRWa3U3ZWtUd2hjUk5zalFFZGt5MXNrZGVUZ0dCaWZkckN1c0lPNndDdzVFOXpsSFFJZHNiVXZ3RnR5dEtGcFoxcXpBem5YTlBKWTB1MG11QXdFTUZWTHpCUnMta05ndl8xVXROWGlDMThLRklTMjFMb2UzaGRaTmNJQzNhcHA2ZFRkcFAtNHMtVVdVaUJuaGNiNDlLSVJQT0E?oc=5", "source_name": "TradingView", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fusion Antibodies reports progress with DR5 project", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPNW9yeWJBd1ZVUUtQQlVzd3k3UEtENUFoZ0ZudnhxWDRKU2R0MDl4ZDNzQWJjeEROaU9QbHZXOFRJd0Vhb2IxMTJtNS1aTUhpSE5RUlNleF9TamJhYmtUTnpuUURuU0I3T21VaXlnN3V5QW54UWZrWWczY1ZQUG5ZTVNGY0pwYXNKOWNEYmVRNVlRT1dLbE1RNFMxUS1zVXBLa3lCeVNPYjBUSUZ3am9j?oc=5", "source_name": "Sharecast.com", "published_at": "2026-06-15T15:10:38+00:00", "published_display": "15 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Fusion Antibodies - Update on grant-funded DR5 project", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQbUV0RVE2RGltVmp5RVpWZF92NVFRTUxjY3ZibHZBQTNFUV90eDBkeG15eXp2WmFRMEZLWlprUFBXeThKOWdUdDhfLXd5YjY4OTdyRXpFM2p0NVNuTXFNVTJ0SUhrN0pyRXlWUlFXbHVsd1o3bDF2NEN2QTZiMjhDeXZPRXVaczBLUC1hdWZXQ2VuSEIyWEVWRzJidkhQZTJuZ2J1em90YmpBREQ1S1lmMEZaYnhuWFZicjYwV1F6VG5BSnVHTGxDWXJzU1E?oc=5", "source_name": "TradingView", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fusion Antibodies plc reports loss of \u00a31.4m in interim results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOZVNrYXBhdHZpemlxa3JIVENuVG1TTnZPc2h3NUVyaTI1RlZIb054dXFzdlZCNjNndElPNFlOSk43dXJOUDhvVXlXOXU3NnZmekhfMHJFOGoycGh3Z2dDUUtUMkZkcmxEdVhORWlQRTZTb2lXMm1vYlRqNm9sOHEydmllaXFLcjRDRzZVY1dNSmZoalR3THhtYW1Dclp5V1dQeHlVZjcxOHh6SEZZeXR1Yi1NQVdmQUVCRXlZQWswRXBpeEMtYlhnQlVRZXh1NEpqcVQydEczTXc3TVdFSlE?oc=5", "source_name": "Belfast Telegraph", "published_at": "2023-12-04T08:00:00+00:00", "published_display": "04 Dec 2023 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBITDA forward of Fusion Antibodies Plc \u2013 LSE:FAB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxONVUxN0g4NlIwSV9HX0todTZBOWQ4cUY3VGh6LVlfUVh6b1Rxb0dfUG55R0pmc3JrSEVtZHdUVmI5aUxfaXBtcXozUjZlTVVDRjhIRFNPTDVBbHhPTzdtY2p1S0ZCR21qWVFYbmlVSWtrVlkxSTVYLWliSXVSaGpuWUp4Nng3STNVY1p1ZzVHOUp3SUxmQWtGdm1XLVNLdncxRmhibW5FcU8?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T07:53:26+00:00", "published_display": "09 Jul 2026 07:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Fusion Antibodies - Holding(s) in Company", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOSEF5VUY0ZVZBbDExOThjLW1fV2tGZzlMUXRWa3U3ZWtUd2hjUk5zalFFZGt5MXNrZGVUZ0dCaWZkckN1c0lPNndDdzVFOXpsSFFJZHNiVXZ3RnR5dEtGcFoxcXpBem5YTlBKWTB1MG11QXdFTUZWTHpCUnMta05ndl8xVXROWGlDMThLRklTMjFMb2UzaGRaTmNJQzNhcHA2ZFRkcFAtNHMtVVdVaUJuaGNiNDlLSVJQT0E?oc=5", "source_name": "TradingView", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fusion Antibodies reports progress with DR5 project", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPNW9yeWJBd1ZVUUtQQlVzd3k3UEtENUFoZ0ZudnhxWDRKU2R0MDl4ZDNzQWJjeEROaU9QbHZXOFRJd0Vhb2IxMTJtNS1aTUhpSE5RUlNleF9TamJhYmtUTnpuUURuU0I3T21VaXlnN3V5QW54UWZrWWczY1ZQUG5ZTVNGY0pwYXNKOWNEYmVRNVlRT1dLbE1RNFMxUS1zVXBLa3lCeVNPYjBUSUZ3am9j?oc=5", "source_name": "Sharecast.com", "published_at": "2026-06-15T15:10:38+00:00", "published_display": "15 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Fusion Antibodies - Update on grant-funded DR5 project", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQbUV0RVE2RGltVmp5RVpWZF92NVFRTUxjY3ZibHZBQTNFUV90eDBkeG15eXp2WmFRMEZLWlprUFBXeThKOWdUdDhfLXd5YjY4OTdyRXpFM2p0NVNuTXFNVTJ0SUhrN0pyRXlWUlFXbHVsd1o3bDF2NEN2QTZiMjhDeXZPRXVaczBLUC1hdWZXQ2VuSEIyWEVWRzJidkhQZTJuZ2J1em90YmpBREQ1S1lmMEZaYnhuWFZicjYwV1F6VG5BSnVHTGxDWXJzU1E?oc=5", "source_name": "TradingView", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fusion Antibodies plc reports loss of \u00a31.4m in interim results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOZVNrYXBhdHZpemlxa3JIVENuVG1TTnZPc2h3NUVyaTI1RlZIb054dXFzdlZCNjNndElPNFlOSk43dXJOUDhvVXlXOXU3NnZmekhfMHJFOGoycGh3Z2dDUUtUMkZkcmxEdVhORWlQRTZTb2lXMm1vYlRqNm9sOHEydmllaXFLcjRDRzZVY1dNSmZoalR3THhtYW1Dclp5V1dQeHlVZjcxOHh6SEZZeXR1Yi1NQVdmQUVCRXlZQWswRXBpeEMtYlhnQlVRZXh1NEpqcVQydEczTXc3TVdFSlE?oc=5", "source_name": "Belfast Telegraph", "published_at": "2023-12-04T08:00:00+00:00", "published_display": "04 Dec 2023 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 79, "total_relevant": 5, "sentiment_summary": {"positive": 0, "negative": 1, "neutral": 4, "score": 47, "total": 5, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 2.2, "count": 4}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 0.11, "latest_week": "2026-07-10", "one_week_move": -8.3, "four_week_move": -8.3, "twelve_week_move": -24.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.85846, "market_dynamics_buy_signal": false, "relative_strength": -24.169145, "fair_value_gap": 37.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 35.1664, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.3% over one week, -8.3% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 3}, {"label": "Sharecast.com", "count": 1}, {"label": "Belfast Telegraph", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 5}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 4}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "5", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.3% over one week, -8.3% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBITDA forward of Fusion Antibodies Plc \u2013 LSE:FAB"}], "updated_at": "2026-07-17T21:23:09.693646+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}